Descripción de la resistencia de Helicobacter pylori a seis antibióticos de uso frecuente en Colombia / Helicobacter pylori susceptibility to six commonly used antibiotics in Colombia

Resumen Helicobacter pylori (H. pylori) es un bacilo gramnegativo microaerófilo, capaz de colonizar la mucosa gástrica. Este microorganismo infecta a más de la mitad de la población mundial, por lo que se ha convertido en la infección bacteriana más común. La prevalencia de la infección y de las enfermedades asociadas a ella es alta, sobre todo en países en vías de desarrollo. El tratamiento recomendado para la erradicación es la triple terapia; sin embargo, su eficacia ha disminuido por el desconocimiento del patrón de susceptibilidad bacteriano por parte del personal médico y dada la aparición de cepas resistentes. La resistencia en H. pylori se asocia con la capacidad de adaptación de la bacteria a ambientes hostiles y al uso de los antibióticos. En Colombia, existen reportes acerca de que H. pylori presenta resistencia a amoxicilina, metronidazol, claritromicina, furazolidona, levofloxacina y tetraciclina. Los estudios del patrón de susceptibilidad determinaron que la frecuencia de resistencia de H. pylori es variable y demuestran la falta de datos en la mayoría del territorio del país. Sobre la base de lo anterior, el objetivo de esta revisión es describir los porcentajes de resistencia de H. pylori a los antibióticos amoxicilina, metronidazol, claritromicina, furazolidona, levofloxacina y tetraciclina, usados en el tratamiento de la infección en los estudios realizados en Colombia.

Abstract Helicobacter pylori (H. pylori) is a microaerophilic gram-negative bacillus that colonizes the gastric mucosa. It infects more than half the world's population, making it the most common bacterial infection. The prevalence of infection and associated diseases is high in developing countries. The recommended treatment for its eradication is triple therapy; however, its efficacy has decreased due to the lack of knowledge of the bacterial susceptibility pattern among the medical staff and the emergence of resistant strains. H. pylori susceptibility is associated with the bacteria's ability to adapt to hostile environments and the use of antibiotics. In Colombia, it has been reported that H. pylori is resistant to amoxicillin, metronidazole, clarithromycin, furazolidone, levofloxacin, and tetracycline. Studies on the susceptibility pattern have determined that the frequency of H. pylori susceptibility is variable and demonstrate the lack of data in most of the Colombian territory. With this in mind, the objective of this review is to describe the percentage of resistance to amoxicillin, metronidazole, clarithromycin, furazolidone, levofloxacin and tetracycline, which are used for the treatment of H. pylori infection, according to studies conducted in Colombia.

Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment / 中南大学学报(医学版)

To investigate the efficacy of bismuth containing quadruple therapies on Helicobacter pylori (Hp) eradication in patients with history of antibiotic treatment. 
 Methods: Hp infected patients (n=327) were allocated into 3 groups. Group A (n=52), patients had no antibiotic history and they took medicine of proton pump inhibitors (PPI) and livzon triple (clarithromycin, tinidazole, and bismuth); group B (n=80), patients had the antibiotic history except for amoxicillin and clarithromycin, and they were treated with PPI, amoxicillin, clarithromycin, and bismuth; group C (n=195), patients suffered failures of Hp therapy or with history of antibiotic abuse, and they were treated with PPI, doxycycline, furazolidone, and bismuth.
 Results: Both the intention-to-treat (ITT) analysis (group A 63.5%, group B 76.2%, group C 82.6%, P<0.05) and the pre-protocol (PP) analysis (group A 76.7%, group B 92.4%, group C 96.4%, P<0.05) showed significant difference among the 3 groups, revealing higher elimination in group B and C. The side-effects (20.2%) were mild and tolerable (group A, 28.0%; group B, 10.7%; group C, 22.0%).
 Conclusion: Proton pump inhibitors together with the livzon triple regimen have a low rate of Hp eradication and a higher incidence of adverse reactions. The quadruple therapy containing clarithromycin and metronidazole drugs can achieve the satisfactory outcomes based on patient's antibiotic history. For patients with multiple antibiotics, the quadruple therapy containing furazolidone and doxycycline may achieve the satisfactory outcomes, but the adverse resction would be relatively higher.

Evaluation of furazolidone, sulfadimidine and amprolium to treat coccidiosis in beetal goats under field conditions

Coccidiosis is a protozoal and occasionally fatal diarrheic disease of goats imposing heavy economic losses to farming community. This study aimed to evaluate the efficacies of Furazolidone, Sulfadimidine and Amprolium against coccidiosis in Beetal goats. Twenty-four [24] Beetal goats naturally infected with coccidiosis were randomly divided into four groups of 6 [A-D]. Goats in groups A, B and C were treated orally with Furazolidone [10mg/Kg], Sulfadimidine [100mg/Kg] and Amprolium [55mg/Kg], respectively for 7 days. Goats in-group D served as positive control. Oocysts per gram [OPG] of feces counts of individual goats in each group were performed on Days; 0 [pre-treatment] 7, 14 and 21 [post-treatment]. OPG counts amongst goats in all groups at day 0 were not significant [P>0.05]. On days 7, 14 and 21, OPG values decreased significantly [P<0.05] in groups A, B and C compared to group D. The efficacy of Furazolidone, Sulfadimidine and Amprolium was 98.6, 98.0 and 99.6 percent, respectively on Day 21 [end of trial]. Statistically, the efficacies of three drugs were not significantly different [P>0.05]. In conclusion, Furazolidone, Sulfadimidine and Amprolium are well-tolerated and any one of these may be recommended to effectively treat coccidiosis in Beetal goats

Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy

We aimed to evaluate the effectiveness and safety of bismuth-containing quadruple therapy plus postural change after dosing for Helicobacter pylori eradication in gastrectomized patients. We compared 76 gastric stump patients with H. pylori infection (GS group) with 50 non-gastrectomized H. pylori-positive patients who met the treatment indication (controls). The GS group was divided into GS group 1 and GS group 2. All groups were administered bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days. GS group 1 maintained a left lateral horizontal position for 30 min after dosing. H. pylori was detected using rapid urease testing and histologic examination of gastric mucosa before and 3 months after therapy. Mucosal histologic manifestations were evaluated using visual analog scales of the updated Sydney System. GS group 1 had a higher prevalence of eradication than the GS group 2 (intention-to-treat [ITT]: P=0.025; per-protocol [PP]: P=0.030), and the control group had a similar prevalence. GS group 2 had a lower prevalence of eradication than controls (ITT: P=0.006; PP: P=0.626). Scores for chronic inflammation and activity declined significantly (P<0.001) 3 months after treatment, whereas those for atrophy and intestinal metaplasia showed no significant change. Prevalence of adverse reactions was similar among groups during therapy (P=0.939). A bismuth-containing quadruple therapy regimen plus postural change after dosing appears to be a relatively safe, effective, economical, and practical method for H. pylori eradication in gastrectomized patients.

comparison between moderate- and high-dose furazolidone in triple regimens for Helicobacter pylori eradication in Iran

Furazolidone has been used as an alternative for clarithromycin or metronidazole in Helicobacterpylori [H. pylori] eradication regimens. In Iran, 14-day Furazolidone-containing quadruple regimens have shown promising eradication rates, but short-course, low dose therapies are always attractive. Therefore, we designed a study to compare the efficacy of two 10-day triple regimens containing moderate and high dose furazolidone for H. pylori eradication. Two hundred and ten patients with peptic ulcer disease who were naive to H. pylori treatment were included. They were randomized into 2 groups: 105 patients received omeprazole 20mg, amoxicillin 1000mg, and furazolidone 200mg [OAF-400], all twice a day for ten days. And the remaining 105 patients received omeprazole 20mg twice a day, amoxicillin 1000mg twice a day and furazolidone 200mg three times a day for ten days [OAF-600]. Urease breath test was performed 8 weeks after the treatment to confirm H. pylori eradication. The intention-to-treat eradication rate was 76.19% in group OAF-400 and 80.95% in group OAF-600 [p=0.38]. Per protocol eradication rates were 81.63% and 89.47%, respectively [p= 0.11]. Severe adverse effects were reported by 8.6% of the patients in group OAF-400 and 5.7% of the patient in group OAF-600 [p=0.1]. However, the total side effects [including mild, moderate, and severe ones] were significantly more prevalent in the OAF-600 group [p=0.001]. None of our triple furazolidone-based regimens [moderate- and high-dose] could achieve the standard eradication rate, and therefore, cannot be considered as a suitable option for first-line treatment

Helicobacter pylori não erradicado com o esquema tradicional: O que fazer? / Helicobacter pylori is not eradicated with traditional scheme: What to do?

O Helicobacter pylori é considerado a infecção mais prevalente no mundo. Sua prevalência é superior a 80% em países em desenvolvimento, com uma parcela de infectados desenvolvendo sintomas e doença, algumas delas com correlação etiopatogênica e resposta terapêutica bem definidas na literatura; outras apresentam estudos com resultados conflitantes, não havendo indicação de tratamento. Apesar de os esquemas de erradicação inicialmente apresentarem índices de sucesso superiores a 90%, falha terapêutica de até 50% tem sido relatada em algumas regiões, decorrente principalmente da resistência aos antibióticos. O desafio atual é identificar os esquemas terapêuticos mais efetivos.

Helicobacter pylori is considered the most prevalent infection worldwide, with its prevalence above 80% in developing countries, having a portion of the infected people developing symptoms and disease, some of them with etiopathogenic correlation and well defined therapeutic response in the literature and other present studies with conflicting results having no indication for treatment. Despite the scheme of eradication initially present successful index rates greater than 90%, therapeutic failure of up to 50% has been reported in some regions, arising mainly to antibiotic resistance. The current challenge is to identify the most effective scheme treatments.

Novel UV-spectrophotometric method for quantitative estimation of furazolidone using mixed hydrotropic agent

A novel, eco friendly, accurate, sensitive, economic and safe spectrophotometric method was developed by application of mixed hydrotropy using 2 M sodium acetate, 8 M urea, 2 M niacinamide and 2 M sodium benzoate solution [25:25:25:25% V/V] as hydrotropic agent, for the solubalizing of poorly water-soluble Furazolidone [FZ] [solubility:- 3.64e-01 mg/mL in water]. There were more than 32 times enhancements in the solubility of FZ were found in mixed hydrotropic solution as compared to solubilities in distilled water. FZ shows maximum absorbance at 360 nm where sodium acetate, urea, niacinamide, sodium benzoate and other tablets excipients did not show any absorbance above 300 nm, and thus no interference in the estimation was seen. FZ was obeyed Beer's law in the concentration range of 10 to 50 micro g/ml r[2]0.9992] in mixed hydrotropic solvent with mean recovery ranging from 97.32% to 98.9%. Proposed method is new, simple, economic, safe, rapid, accurate and reproducible and was validated according to ICH guidelines and values of accuracy, precision and other statistical analysis were found to be in good accordance with the prescribed values

Probiotics for the treatment of pediatric helicobacter pylori infection: a randomized double blind clinical trial

Helicobacter pylori is recognized as a major etiological factor in the pathogenesis of gastritis and peptic ulcer disease. H. Pylori eradication has a failure rate of more than 30% in pediatric patients, particularly because of poor compliance, antibiotic resistance and occurrence of side-effects. This study was aimed to determine whether adding the probiotics to a standard anti-H. pylori regimen could minimize the gastrointestinal side-effect prevalence and improve the eradication rate. Double-blind randomized placebo controlled study conducted at Children's Medical Center in Tehran, Iran. Sixty six H. pylori positive children were treated with a triple drug treatment protocol [omeprazole+amoxycillin+furazolidon] and randomly allocated to receive either probiotic or placebo. All patients underwent esophagogastroduodenoscopy. H. pylori infection was diagnosed by either rapid urease test [RUT] or histology. H. pylori status was assessed after 4-8 weeks of the completion of treatment with stool H. pylori antigen test. The side effects of the treatment were determined in each group. Mean age of patients was 9.09 [range 3-14] years, 44 [65.7%] patients were boys [sex ratio 2:1]. All 66 patients completed the course of treatment and follow-up. The rate of H. pylori eradication was significantly higher in probiotic group [P=0.04]. In probiotic supplemented children there was a lower rate of nausea/vomiting [P=0.02] and diarrhea [P=0.039] during treatment. This study showed that probiotics have positive effect on the eradication of H. pylori infection. Adjuvant therapy with probiotic is recommended in order to reduce the frequency of antibiotic induced side-effects during treatment with antibiotics

[Evaluation of furazolidone reabsorption in the dog bladder following ileocystoplasty]

Drug absorption within intestinal urinary diversions has been reported to cause prolonged and higher grade toxicity. The aim of this study has been to determine the importance and significance of drug absorption via neobladder after ileocystoplasty. Ten healthy adult mixed breed dogs of both sexes [7 males and 3 females], weighing between 15-25 kg were selected. The animals were randomly divided into equal test and control groups. In treatment group, partial cytectomy, resecting 50 percent of the bladder and immediate ileocystoplasty was performed by Lamesch and Dociu technique. In control group an ileal resection and intestinal tract re-anastomosis was achieved without partial cystectomy and ileocystoplasty. In all animals, blood and urine samples were taken before surgery, at hours 1, 3, 6 and 24 after oral administration of Furazolidone [100 mg/dog] and this process was repeated on days 7, 25 and 45 after operation at the same hours. After preparation of the samples, the Furazolidone was measured by HPLC assay. One way analysis of variance and Dunnet test were used for the analysis of the data and P values less than 0.05 were considered statistically significant. In test group, the blood samples showed significant changes of Furazolidone on day 25. The urine samples revealed significant changes on day 45 in both groups and on day 25 in test group. The results of this study showed absorptive effect of the ileum that decreases with time. Problems arising from drug reabsorption are usually rare and in most drugs a change in dosage [except those which have a narrow

[Evaluation of efficacy of H. pylori eradication regimens in Iran: a systematic review]

Treatment regimens for the eradication of H. pylori as suggested in Western studies may not be applicable for Iran. Herein, we conduct a systematic review to ascertain the efficacy of eradication therapy regimens used for Iranian patients and introduce the more successful treatment regimens for Iranians. This review was a comprehensive search of English and Farsi electronic databases conducted from June to September 2011. A total of 11 trials were included in our study. In these, there were 28 different eradication regimens studied. Of the 28 regimens, 8 had an H. pylori eradication rate of over 85% and in 3 the eradication rate was greater than 90%. In Iran, the regimens that contained amoxicillin-furazolidone or amoxicillin-clarithromycin for two weeks were the most effective for H. pylori eradication, although the furazolidone-based regimen was less expensive. For first-line treatment, the amoxicillin-furazolidone-based regimen for 2 weeks is cost-effective for H. pylori eradication in Iranian patients

Comparison of the Antibiotic Resistance of Helicobacter pylori Isolated in Jinju Over a 15-year Period

The aims of this study were to investigate the changing pattern of Helicobacter pylori antibiotic resistance in Jinju over a 15-year period. H. pylori strains were isolated from 170 adults living in Jinju from 1985-1989, 1990-1994 and 1995-1999, and from 23 adults living in Cheongju from 1995 to 1999. Susceptibility to erythromycin, clarithromycin, azithromycin, amoxicillin, tetracycline, metronidazole, furazolidone, levofloxacin, ciprofloxacin, moxifloxacin, and rifabutin was tested using the serial two-fold agar dilution method. Moxifloxacin resistance significantly increased in Jinju from 1985-1989 (0%) to 1995-1999 (14.9%) (p < 0.0001). Resistance to amoxicillin was increasesed trend to decreased trend from 1985 to 1999 (p = 0.033), whereas metronidazole resistance decreased from 37.5% to 21.3%. Resistance to furazolidone was greater from 1985-1989 (9.4%) than in 1995-1999 (2.1%). In comparing Jinju and Cheongju, minimal inhibitory concentrations (MICs) of tetracycline and levofloxacin among H. pylori isolated from Jinju were lower than for isolates from Cheonju (p < 0.05). The levofloxacin resistance rate was higher in Cheongju than in Jinju (p = 0.02). No macrolide resistance was observed in Cheongju. Overall, we did not observe any remarkable antimicrobial resistance increase of H. pylori strains isolated from Jinju over 15 years. The MIC distributions of antimicrobials and antimicrobial resistant rates were time- and region-specific among different strains. Future anti-H. pylori eradication regimens should be designed based on the changing patterns of antimicrobial resistance according to the resident area.

Inhibition of shrimp pathogenic vibrios by extracellular compounds from a proteolytic bacterium Pseudomonas sp. W3 / Inhibición de vibrios patógenos del camarón por compuestos extracelulares de una bacterias proteolítica Pseudomonas sp.W3

Pseudomonas sp. W3, a bacterium known to produce an extracellular alkaline protease, secreted secondary metabolites that inhibited pathogenic bacteria responsible for shrimp luminous vibriosis disease. Antivibrio compounds in the culture supernatant or culture filtrates (0.45 um and 0.22 um) of the isolate W3 were tested using an agar well diffusion method on a number of pathogenic vibrios. Vibrio harveyi PSU 2015 a pathogenic isolate was the most sensitive strain. The effectiveness of preparations from the isolate W3 against V. harveyi PSU 2015, and V. cholerae PSSCMI 0062 was in the order of culture supernatant > 0.45 um culture filtrate > 0.22 um culture filtrate. These extracellular antivibrio compounds also lysed both dead and living cells of V. harveyi PSU 2015. Results of the partial characterization tests indicated that there was some particulate antivibrio compound that was destroyed by treatment with enzymes particularly alpha-chymotrypsin, autoclaving at 121ºC for 15 min and was mostly removed by filtration through a 0.22 µm filter. Most of the inhibitory compounds were of small molecular weight able to pass through a 0.22 um filter and were resistant to treatment with various enzymes, pH values between 4-8 and temperatures up to 121ºC for 30 min. The optimum pH for the antivibrio activity in the 0.45 um culture filtrate was between pH 6-7.

Effect of birid triple viable on peptic ulcer patients with Helicobacter pylori infection / 中南大学学报(医学版)

OBJECTIVE@#To observe the effect of birid triple viable on peptic ulcer patients with Helicobacter pylori(H.pylori) infection.@*METHODS@#A total of 120 peptic ulcer patients with H.pylori infection was randomly divided into 2 groups. The control group was treated with the triple therapy including Esomeprazole, Amoxicillin, and Furazolidone. The treatment group was treated with the same triple therapy plus birid triple viable. The pH values of the gastric juice, bacterial culture of the gastric juice, the therapy-related side effects and the healing rate of ulcer and erosive were observed before the treatment and after a 14-day-treatment respectively. The (14)C-urea breath test((14)C-UBT) was used to evaluate the H.pylori eradication rates 4 weeks after the treatment.@*RESULTS@#After the treatment, pH values of the gastric juice in both groups were significantly higher than those before the treatment (P0.05),while the healing rate of erosion in the treatment group was higher than that of the control group (P<0.05).The H.pylori eradication rates evaluated by per-protocol (PP) analysis in the treatment group was significantly higher than that of the control group (80.4% and 62.4% respectively, P<0.05).@*CONCLUSION@#The combined use of birid triple viable and the triple therapy of H.pylori in peptic ulcer patients with H.pylori infection can reduce the bacteria of the gastric juice and therapy-related side effects. It can increase the H.pylori eradication rate and promote the healing of erosion.

Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate and omeprazole for eradication of helicobacter pylori

Resistance to metronidazole is one of the most common reasons for Helicobacter pylori treatment failure with the classic triple therapy. The clarithromycin-based regimen is not cost-effective for use in developing countries. Though furazolidone is a great substitute it has many side effects. Decreasing the duration of treatment with furazolidone to 1 week may help decrease the drug's side effects. to study the efficacy and side effects of furazolidone when given for 1 week in combination with bismuth subcitrate, amoxicillin, and omeprazole. One hundred and seventy-seven patients with duodenal ulcer were randomly divided into two groups. Group I received omeprazole 2 x 20 mg + amoxicillin 2 x 1 g + bismuth subcitrate 4 x 120 mg for 2 weeks, with furazolidone 2 x 200 mg in the first week only. Group II received the same regimen, except that 1 week of furazolidone was followed by 1 week of metronidazole in the second week. Control endoscopy was performed after 6 weeks. Three biopsies from the antrum and three from the corpus were taken for urease testing and histology. Eradication was concluded if all tests were negative for H pylori. One hundred and fifty-seven patients completed the study. Two subjects from group I and three from group II did not tolerate the regimen and were excluded from the analysis. No serious complication was detected in any patient. The eradication rates by per-protocol [PP] analysis and intention-to-treat [ITT] analysis were 89% and 79.3% in group I and 86.6% and 74.4% in group II, respectively. One week of furazolidone in combination with 2 weeks of amoxicillin, omeprazole, and bismuth subcitrate is a safe and cost-effective regimen for the eradication of H pylori. Adding metronidazole to the above regimen does not increase the eradication rate

Furazolidona, tetraciclina e omeprazol: uma alternativa de baixo custo para erradicação de Helicobacter pylori em crianças / Furazolidone, tetracycline and omeprazole: a low-cost alternative for Helicobacter pylori eradication in children

OBJETIVOS: Avaliar furazolidona, tetraciclina e omeprazol como tratamento de primeira linha para Helicobacter pylori em crianças com sintomas digestivos. MÉTODOS: Ensaio clínico aberto, prospectivo e consecutivo. O estudo incluiu pacientes acima de 8 anos com dispepsia funcional, dor abdominal funcional, anormalidades histológicas graves (metaplasia intestinal, atrofia gástrica ou linfoma do tecido linfóide associado às mucosas) ou úlcera péptica. A presença de H. pylori foi definida com base em exame histológico e teste da urease. O regime medicamentoso consistiu de um tratamento de 7 dias com omeprazol, tetraciclina (ou doxiciclina) e furazolidona duas vezes por dia. A erradicação foi avaliada através de endoscopia digestiva alta 2 meses após o tratamento (exame histológico e teste da urease). Avaliações clínicas posteriores foram realizadas 7 dias e 2 meses após o tratamento. RESULTADOS: Foram incluídos 36 pacientes (21 meninas/15 meninos). A idade variou de 8 a 19 anos (média de 12,94+2,89 anos). Na análise por intenção de tratar (n = 36), a taxa de erradicação foi de 83,3 por cento (IC95 por cento 77,1-89,5), ao passo que na análise por protocolo (n = 29), foi de 89,7 por cento (IC95 por cento 84,6-94,7). A adesão foi melhor quando se utilizou doxiciclina, mas as taxas de sucesso foram semelhantes para as duas tetraciclinas. Não houve nenhuma variável associada à falha no tratamento. Foram relatados efeitos colaterais em 17 pacientes (47,2 por cento), principalmente dor abdominal (11/30,5 por cento), náusea (sete/19,4 por cento) e vômitos (cinco/13,9 por cento). CONCLUSÃO: A terapia tripla com furazolidona e tetraciclina é uma alternativa de baixo custo para o tratamento da infecção pelo H. pylori.

OBJECTIVE: To evaluate furazolidone, tetracycline and omeprazole as first line therapy for Helicobacter pylori in children with digestive symptoms. METHODS: Prospective and consecutive open trial. The study included patients older than 8 years old with functional dyspepsia, functional abdominal pain, severe histological abnormalities (intestinal metaplasia, gastric atrophy or mucosa-associated lymphoid tissue lymphoma) or peptic ulcer. H. pylori status was defined based both upon histology and rapid urease test. Drug regimen was a 7-day course of omeprazol, tetracycline (or doxycycline) and furazolidone twice daily. Eradication was assessed by upper endoscopy 2 months after treatment (histology and rapid urease test). Further clinical evaluation was done 7 days and 2 months after treatment. RESULTS: Thirty-six patients (21 female/15 male) were included. Age ranged from 8 to 19 years (mean 12.94+2.89 years). On intention-to-treat analysis (n = 36), eradication rate was 83.3 percent (95 percentCI 77.1-89.5) whereas in per-protocol analysis (n = 29), it was 89.7 percent (95 percentCI 84.6-94.7). Compliance was better when doxycycline was used, but the success rates were similar for the two tetracyclines. There was no variable associated with treatment failure. Side effects were reported in 17 patients (47.2 percent), mainly abdominal pain (11/30.5 percent), nausea (seven/19.4 percent) and vomiting (five/13.9 percent). CONCLUSION: Triple therapy with furazolidone and tetracycline is a low-cost alternative regimen to treat H. pylori infection.

Studies on the residues of terramycin and furazolidone in broiler meat--a public health concern.

The concentration of Terramycin and Furazolidone residues in broiler meat following their subtherapeutic use in the ration of the birds were detected as 296 ng/g, 174 ng/g, 40 ng/g, 60 ng/g and 124 ng/ml in kidney, liver, thigh muscle, breast muscle and serum for Terramycin and 270 ng/g 160 ng/g and 88 ng/ml in kidney, liver and serum for Furazolidone. One week of withdrawal period from the antibiotic in feed/water was sufficient to render the meat free from residues.

Efficacy of 4 kinds of triple strategy for Helicobacter pylori eradication / 中南大学学报(医学版)

OBJECTIVE@#To evaluate the efficacy and safety of 4 kinds of triple strategy of Helicobacter pylori (Hp) eradication.@*METHODS@#A total of 307 patients who suffered from Hp infection, confirmed by rapid urease test (RUT) and 14C-urea breath test (UBT),were randomly divided into 4 groups. Each group had 80, 76, 77, and 74 patients respectively. Group A was treated with rabeprazole, clarithromycin, and furazolidone (RCF); Group B with ranitidine bismuth citrate, clarithromycin, and furazolidone (BCF); Group C with rabeprazole, amoxicillin, and furazolidone (RAF); while Group D with ranitidine bismuth citrate, amoxicillin, and furazolidone (BAF). Hp was detected by RUT and UBT at 4 weeks after later treatment.@*RESULTS@#Hp eradication rates of group A,B,C, and D were 90.0%,67.1%,62.3%,and 45.9%,respectively. The difference between Group A and Group B, Group A and Group C was significant (P<0.05). Eradication rate of Group B and C was higher than that of Group D (P<0.05). There was no statistical difference between the eradication rate of Group B and C, and among the side effects of the 4 groups.@*CONCLUSION@#The strategy of RCF was the best among the 4 triple strategy of Hp eradication, which can be used clinically.